March 17, 2010
Institutional Review Board, Hospital for Special Surgery
The safety of our participants is our top priority. The trial/study is approved and periodically reviewed by the Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial or research study, the investigator will explain the purpose of the trial/study, its expected benefits, any possible risks or side effects, and what your role will be. If you want to join the trial/study, you must sign informed consent documents. You can leave a trial/study at any time without penalty.
For further information, see Understanding Clinical Trials/Research Studies.
Douglas E. Padgett, MD
Michael M. Alexiades, MD
Friedrich Boettner, MD
Robert L. Buly, MD
Struan H. Coleman, MD, PhD
Alejandro Gonzalez Della Valle, MD
David L. Helfet, MD
Dean G. Lorich, MD
David J. Mayman, MD
Michael J. Maynard, MD
Peter J. Moley, MD
Danyal H. Nawabi, MD
Bryan J. Nestor, MD
Amar S. Ranawat, MD
Anil S. Ranawat, MD
Edwin P. Su, MD
Roger F. Widmann, MD
This is an observational study including all patients who present to the Center for Hip Preservation with a primary diagnosis of hip pain. The enrollment period and duration of follow-up is indefinite.
Inclusion Criteria:
• Patients who present to the Center for Hip Preservation
• Primary diagnosis of hip pain
Exclusion Criteria:
• Patients who do not consent to take part in the registry
• Patients diagnosed with advanced osteoarthritis
• Patients who have undergone total hip arthroplasty or resurfacing
• Patients who are indicated for total hip arthroplasty or resurfacing